Back to Search Start Over

CPP impairs contextual learning at concentrations below those that block pyramidal neuron NMDARs and LTP in the CA1 region of the hippocampus.

Authors :
Laha K
Zhu M
Gemperline E
Rau V
Li L
Fanselow MS
Lennertz R
Pearce RA
Source :
Neuropharmacology [Neuropharmacology] 2022 Jan 01; Vol. 202, pp. 108846. Date of Electronic Publication: 2021 Oct 20.
Publication Year :
2022

Abstract

Drugs that block N-methyl-d-aspartate receptors (NMDARs) suppress hippocampus-dependent memory formation; they also block long-term potentiation (LTP), a cellular model of learning and memory. However, the fractional block that is required to achieve these effects is unknown. Here, we measured the dose-dependent suppression of contextual memory in vivo by systemic administration of the competitive antagonist (R,S)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP); in parallel, we measured the concentration-dependent block by CPP of NMDAR-mediated synapses and LTP of excitatory synapses in hippocampal brain slices in vitro. We found that the dose of CPP that suppresses contextual memory in vivo (EC50 = 2.3 mg/kg) corresponds to a free concentration of 53 nM. Surprisingly, applying this concentration of CPP to hippocampal brain slices had no effect on the NMDAR component of evoked field excitatory postsynaptic potentials (fEPSP <subscript>NMDA</subscript> ), or on LTP. Rather, the IC50 for blocking the fEPSP <subscript>NMDA</subscript> was 434 nM, and for blocking LTP was 361 nM - both nearly an order of magnitude higher. We conclude that memory impairment produced by systemically administered CPP is not due primarily to its blockade of NMDARs on hippocampal pyramidal neurons. Rather, systemic CPP suppresses memory formation by actions elsewhere in the memory-encoding circuitry.<br /> (Copyright © 2021 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1873-7064
Volume :
202
Database :
MEDLINE
Journal :
Neuropharmacology
Publication Type :
Academic Journal
Accession number :
34687710
Full Text :
https://doi.org/10.1016/j.neuropharm.2021.108846